NCT07322120Not yet recruiting
Light Fasting Diet and Magnesium in Polycystic Ovary Syndrome (PCOS)
Investigation of the Effect of Light Fasting Diet Combined With Magnesium Supplementation on Lipid Profile, Lipid Peroxidation, and C-Reactive Protein (CRP) Levels in Women With Polycystic Ovary Syndrome (PCOS).
Source: ClinicalTrials.gov · Last updated 7 Jan 2026
Brief summary (registry, in English)
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, which is associated with hormonal imbalances, dyslipidemia, chronic inflammation, and increased oxidative stress, and can increase the risk of cardiovascular and metabolic diseases. Evidence suggests that nutritional interventions play an important role in improving metabolic outcomes in these patients. This study is a randomized, triple-blind, controlled clinical trial designed to investigate the effect of a light fasting diet combined with magnesium supplementation on lipid profile, lipid peroxidation (malondialdehyde), and C-reactive protein (CRP) levels in women with PCOS. In this study, 46 eligible women were randomly divided into two groups receiving a light fasting diet with magnesium supplementation or placebo, and changes in biochemical and anthropometric indices were evaluated before and after 8 weeks of intervention.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 22 Dec 2025
- Start date
- 20 Feb 2026
- Primary completion date
- 22 May 2026
- Lead sponsor
- Behnood Abbasi
- NCT number
- NCT07322120
What you commit to
- Study type: Interventional
- Planned participants: 46
- From 20 Feb 2026 to the primary completion date, 22 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of drug therapy that affects carbohydrate or fat metabolism (including oral contraceptives, insulin sensitizers, antiepileptic drugs, antipsychotics, statins, and fish oil) within the past 6 months.
Other illness
- Failure of the participant to cooperate during the study
- Presence of other diseases (such as congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, hyperprolactinemia, diabetes, thyroid disease, severe cardiovascular, gastrointestinal, renal, and hepatic diseases)
Other
- Planning for pregnancy, pregnant, or breastfeeding
- In the perimenopausal stage
- Low blood pressure
- Performing high-intensity exercise
Who the study is looking for
- People between the ages of 19 and 65
- People with a body mass index (BMI) ≤ 25
- Diagnosis of polycystic ovary syndrome by a specialist based on the Rotterdam criteria
Age in the registry: 19 years to 65 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.